SWTX vs. IOVA, APGE, ACLX, IMCR, IBRX, CGON, IMVT, DNLI, VCEL, and KYMR
Should you be buying SpringWorks Therapeutics stock or one of its competitors? The main competitors of SpringWorks Therapeutics include Iovance Biotherapeutics (IOVA), Apogee Therapeutics (APGE), Arcellx (ACLX), Immunocore (IMCR), ImmunityBio (IBRX), CG Oncology (CGON), Immunovant (IMVT), Denali Therapeutics (DNLI), Vericel (VCEL), and Kymera Therapeutics (KYMR). These companies are all part of the "biological products, except diagnostic" industry.
Iovance Biotherapeutics (NASDAQ:IOVA) and SpringWorks Therapeutics (NASDAQ:SWTX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.
Iovance Biotherapeutics' return on equity of -65.69% beat SpringWorks Therapeutics' return on equity.
77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 10.4% of Iovance Biotherapeutics shares are owned by company insiders. Comparatively, 7.6% of SpringWorks Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Iovance Biotherapeutics presently has a consensus price target of $24.64, suggesting a potential upside of 107.73%. SpringWorks Therapeutics has a consensus price target of $68.00, suggesting a potential upside of 54.55%. Given SpringWorks Therapeutics' higher possible upside, equities research analysts clearly believe Iovance Biotherapeutics is more favorable than SpringWorks Therapeutics.
Iovance Biotherapeutics received 469 more outperform votes than SpringWorks Therapeutics when rated by MarketBeat users. Likewise, 74.47% of users gave Iovance Biotherapeutics an outperform vote while only 67.69% of users gave SpringWorks Therapeutics an outperform vote.
SpringWorks Therapeutics has higher revenue and earnings than Iovance Biotherapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Iovance Biotherapeutics had 2 more articles in the media than SpringWorks Therapeutics. MarketBeat recorded 8 mentions for Iovance Biotherapeutics and 6 mentions for SpringWorks Therapeutics. Iovance Biotherapeutics' average media sentiment score of 0.45 beat SpringWorks Therapeutics' score of 0.12 indicating that SpringWorks Therapeutics is being referred to more favorably in the news media.
Iovance Biotherapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.
Summary
Iovance Biotherapeutics beats SpringWorks Therapeutics on 11 of the 16 factors compared between the two stocks.
Get SpringWorks Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SpringWorks Therapeutics Competitors List
Related Companies and Tools
